Annual Meeting Proceedings, Part 2American Society of Clinical Oncology, 2006 |
Other editions - View all
Common terms and phrases
adjuvant adv RCC adverse events Annual Meeting ASCO AstraZeneca atamestane Background breast cancer Bristol-Myers Squibb Ca/D Cancer Center Cancer Institute Cancer Oral Presentation capecitabine chemotherapy cisplatin Clinical Oncology commercial interest cycles D2+PAND disclosure disease Docetaxel drugs DTIC efficacy Eli Lilly enrolled Exemestane first-line fluorouracil gastric cancer Gastrointestinal Noncolorectal gemcitabine hazard ratio Hospital IFN a2b IFN-a immediate family member-defined invasive breast cancer involving the sharing Italy Journal of Clinical letrozole matter under consideration median TTP Medical member-defined as someone metastatic mg/m² months mRCC mths non-inferiority non-T adjRx Novartis NSABP Oncology overall survival oxaliplatin patients pts PCR rates Pfizer phase III trial poor-risk postmenopausal primary endpoint prior adjuvant raloxifene randomized phase regimen relationship involving Results sanofi-aventis sharing of income significant differences Society of Clinical sunitinib tamoxifen TEMSR Tier toremifene toxicity treatment TRTFU University Wyeth Research